(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl hydrogen carbonate | 106207-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl hydrogen carbonate
• 英文别名: (2,4-dioxopyrimidin-1-yl)methyl hydrogen carbonate
• CAS: 106207-00-5
• 化学式: C₆H₆N₂O₅
• 分子量: 186.12
• InChiKey: UEHYWGOGEOIRCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Compositions and Methods for Diagnosing and Treating Cancer
  申请人：Oncomed Pharmaceuticals, Inc.

  公开号：EP2511298A2

  公开（公告）日：2012-10-17

  The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

  本发明涉及表征、诊断和治疗癌症的组合物和方法。特别是本发明提供了诊断、表征、预后和治疗癌症的手段和方法，特别是针对癌症干细胞的手段和方法。本发明提供了一种可溶性 FZD 受体，它包含人类 FZD 受体的胞外结构域，可抑制肿瘤细胞的生长。本发明还进一步提供了一种包含人FZD受体的Fri结构域的可溶性受体，该受体结合人FZD受体的配体，所述可溶性受体能够抑制肿瘤生长。本发明还进一步提供了一种治疗癌症的方法，该方法包括施用一种可溶性FZD受体，该受体包括例如人FZD受体的胞外结构域或人FZD受体的Fri结构域，其量可有效抑制肿瘤生长。
• PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES
  申请人：Abbott Molecular Inc.

  公开号：EP3988658A1

  公开（公告）日：2022-04-27

  The present disclosure relates to systems and methods for purifying nucleic acid. In particular, the present disclosure relates to systems and methods for purifying nucleic acids using metal or metal oxide compositions.

  本公开涉及用于纯化核酸的系统和方法。特别是，本公开涉及使用金属或金属氧化物组合物纯化核酸的系统和方法。
• Purification of nucleic acids using copper-titanium oxides
  申请人：ABBOTT MOLECULAR INC.

  公开号：US11015187B2

  公开（公告）日：2021-05-25

  The present disclosure relates to systems and methods for purifying nucleic acid. In particular, the present disclosure relates to systems and methods for purifying nucleic acids using metal or metal oxide compositions.

  本公开涉及用于纯化核酸的系统和方法。特别是，本公开涉及使用金属或金属氧化物组合物纯化核酸的系统和方法。
• C3D cellular and acellular vaccines for the prevention and treatment of cancer
  申请人：The Regents of the University of Michigan

  公开号：US11214603B2

  公开（公告）日：2022-01-04

  The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

  本发明涉及癌症的治疗以及癌症生长和/或转移的预防。特别是，本发明涉及含有补体（C3）蛋白水解产物 C3d 的细胞疫苗和无细胞疫苗，以及使用本发明增强宿主对癌症的免疫反应（如 T 细胞介导的免疫反应）的方法。本发明的组合物和方法可单独或与其他癌症疗法一起用于治疗通过逃避宿主免疫监视和/或反应（如T细胞介导的免疫反应）而发展和/或持续存在的淋巴瘤和/或癌症。本发明的组合物和方法可用于临床和研究领域，例如生物学、免疫学、医学和肿瘤学领域。
• Compositions and methods for identifying drug resistant tuberculosis
  申请人：ABBOTT MOLECULAR INC.

  公开号：US11225693B2

  公开（公告）日：2022-01-18

  Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.

  本文提供了用于诊断和鉴定结核病感染的组合物和方法。特别是，本文提供了用于鉴定抗药性结核病的组合物和方法。